The Effect of 17α-Hydroxyprogesterone Caproate on Preterm Birth in Women with an Ultrasound-Indicated Cerclage

ABSTRACT

We sought to determine if 17α-hydroxyprogesterone caproate (17P) reduces the rate of preterm birth (PTB) in women with an ultrasound-indicated cerclage (UIC). We retrospectively reviewed a cohort of women with a previous spontaneous PTB and current UIC placement for cervical length (CL) < 25 mm at < 23⁶/₇ weeks. The study group consisted of women treated with 17P; the control group consisted of women not treated with 17P. Primary outcome was spontaneous PTB < 35 weeks. Secondary outcomes included PTB < 32 weeks, PTB < 28 weeks, gestational age at delivery, and birth weight. A total of 58 women were identified; 15 (25.9%) received 17P, and 43 (74.1%) did not. 17P did not have a significant effect on PTB < 35 weeks (odds ratio 1.72, 95% confidence interval 0.50 to 5.89), nor did it have a significant effect on the secondary outcomes. Among women with a prior spontaneous PTB and current UIC for CL < 25 mm, 17P did not reduce the rate of PTB < 35 weeks.

KEYWORDS

Preterm birth - progesterone - short cervical length - ultrasound-indicated cerclage

REFERENCES

• 1 Martin J A, Hamilton B E, Sutton P D Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System et al. Births: final data for 2005.  Natl Vital Stat Rep. 2007;  56 1-103
• 2 Owen J, Yost N, Berghella V National Institute of Child Health and Human Development, Maternal-Fetal Medicine Units Network et al. Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth.  JAMA. 2001;  286 1340-1348
• 3 Berghella V, Odibo A O, To M S, Rust O A, Althuisius S M. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data.  Obstet Gynecol. 2005;  106 181-189
• 4 Owen J, Hankins G, Iams J D et al.. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length.  Am J Obstet Gynecol. 2009;  201 375 e1-e8
• 5 Meis P J, Klebanoff M, Thom E National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.  N Engl J Med. 2003;  348 2379-2385
• 6 Society for Maternal Fetal Medicine Publications Committee . ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.  Obstet Gynecol. 2008;  112 (4) 963-965
• 7 Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-α-hydroxyprogesterone caproate.  Am J Obstet Gynecol. 2007;  196 453 e1-e4 discussion 421
• 8 Berghella V, Figueroa D, Szychowski J M Vaginal Ultrasound Trial Consortium et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.  Am J Obstet Gynecol. 2010;  202 351 e1-e6
• 9 Rebarber A, Cleary-Goldman J, Istwan N B et al.. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.  Am J Perinatol. 2008;  25 271-275
• 10 Hardy D B, Janowski B A, Corey D R, Mendelson C R. Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression.  Mol Endocrinol. 2006;  20 2724-2733
• 11 Grazzini E, Guillon G, Mouillac B, Zingg H H. Inhibition of oxytocin receptor function by direct binding of progesterone.  Nature. 1998;  392 509-512
• 12 Durnwald C P, Lynch C D, Walker H, Iams J D. The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time.  Am J Obstet Gynecol. 2009;  201 410 e1-e5
• 13 Kiefer D G, Keeler S M, Rust O A, Wayock C P, Vintzileos A M, Hanna N. Is midtrimester short cervix a sign of intraamniotic inflammation?.  Am J Obstet Gynecol. 2009;  200 374 e1-e5
• 14 Facchinetti F, Dante G, Venturini P, Paganelli S, Volpe A. 17α-hydroxy-progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery.  Am J Perinatol. 2008;  25 503-506
• 15 Keeler S M, Kiefer D, Rochon M, Quinones J N, Novetsky A P, Rust O. A randomized trial of cerclage vs. 17 α-hydroxyprogesterone caproate for treatment of short cervix.  J Perinat Med. 2009;  37 473-479